GalliaGeorgetteLevyMD

PubMed

• 10 citations
  Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
  Anna Kiialainen, Markus Niggli, Christine L Kempton, Giancarlo Castaman, Tiffany Chang, Ido Paz-Priel, Joanne I Adamkewicz, Gallia G Levy> ;Haemophilia. 2022 Nov 1
• 3 citations
  Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3.
  Michael U Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Víctor Jiménez-Yuste, Mi...> ;Research and Practice in Thrombosis and Haemostasis. 2022 Aug 1
• 4 citations
  A Model-Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients with Hemophilia A
  Koichiro Yoneyama, Christophe Schmitt, Tiffany Chang, Christophe Dhalluin, Sayaka Nagami, Claire Petry, Gallia G. Levy> ;Journal of Clinical Pharmacology. 2021 Sep 21
• 16 citations
  The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN ...
  Mark W. Skinner, Claude Negrier, Ido Paz-Priel, Sammy Chebon, Víctor Jiménez-Yuste, Michael U. Callaghan, Michaela Lehle, Markus Niggli, Johnny Mahlangu, Amy D. Shapir...> ;Haemophilia. 2021 Jun 25
• 50 citations
  Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
  Christophe Schmitt, Joanne I. Adamkewicz, Jin Xu, Claire Petry, Guy Young, Claude Negrier, Michael U. Callaghan, Gallia G. Levy> ;Thrombosis and Haemostasis. 2021 Mar 1
• 122 citations
  Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
  Michael U. Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse-Jarres, Maria Elisa Mancuso...> ;Blood. 2020 Dec 10
• 8 citations
  Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study.
  Johannes Oldenburg, Midori Shima, Rebecca Kruse-Jarres, Elena Santagostino, Johnny Mahlangu, Michaela Lehle, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Peter Tr...> ;Pediatric Blood & Cancer. 2020 Aug 9
• 21 citations
  A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
  Genmin Lu, Pamela B. Conley, Janet M. Leeds, Mark Karbarz, Gallia Levy, Vandana Mathur, Janice Castillo, Mark Crowther, John T. Curnutte> ;Blood Advances. 2020 Feb 25
• 216 citations
  A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
  Guy Young, Ri Liesner, Tiffany Chang, Robert F. Sidonio, Johannes Oldenburg, Víctor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen,...> ;Blood. 2019 Dec 12
• 44 citations
  Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
  Gallia G. Levy, Elina Asikanius, Peter J. Kuebler, Soraya Benchikh El Fegoun, Sille Esbjerg, Stephanie Seremetis> ;Journal of Thrombosis and Haemostasis. 2019 Sep 1
• 198 citations
  Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised ...
  Steven W. Pipe, Midori Shima, Michaela Lehle, Amy D. Shapiro, Sammy Chebon, Katsuyuki Fukutake, Nigel S. Key, Agnès Portron, Christophe Schmitt, Maria Podolak-Dawidzia...> ;The Lancet. Haematology. 2019 Jun 1
• 27 citations
  Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS).
  Johnny Mahlangu, Johannes Oldenburg, Michael U. Callaghan, Midori Shima, Maria Elisa Mancuso, Peter Trask, Michael Recht, Claudia Garcia, Renchi Yang, Michaela Lehle, ...> ;Haemophilia. 2019 May 1
• 17 citations
  Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study.
  Johnny Mahlangu, Johannes Oldenburg, Michael U. Callaghan, Midori Shima, Elena Santagostino, Maggie Moore, Michael Recht, Claudia Garcia, Renchi Yang, Michaela Lehle, ...> ;Haemophilia. 2018 Nov 1
• 58 citations
  A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
  Koichiro Yoneyama, Christophe Schmitt, Naoki Kotani, Gallia G. Levy, Ryu Kasai, Satofumi Iida, Midori Shima, Takehiko Kawanishi> ;Clinical Pharmacokinetics. 2018 Sep 1
• 406 citations
  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
  Johnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, Claude Negrier, Markus Niggli, M Elisa Mancuso, Christophe Schmitt, Víctor Jiménez-Yuste, Christine L. Kempton, Chr...> ;The New England Journal of Medicine. 2018 Aug 29
• 201 citations
  Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled...
  Ian E. Krop, Ingrid A. Mayer, Vinod Ganju, Maura N. Dickler, Stephen R. D. Johnston, Serafin Morales, Denise A. Yardley, Bohuslav Melichar, Andres Forero-Torres, Soo-C...> ;The Lancet. Oncology. 2016 Jun 1
• Evidence for superconductivity in Li-decorated monolayer graphene.
  Ludbrook BM, Levy G, Nigge P, Zonno M, Schneider M, Dvorak DJ, Veenstra CN, Zhdanovich S, Wong D, Dosanjh P, Straßer C, Stöhr A, Forti S, Ast CR, Starke U, Damascelli A> ;Proc. Natl. Acad. Sci. U.S.A.. 2015-09-22
• Long- versus Short-Range Scattering in Doped Epitaxial Graphene.
  Straßer C, Ludbrook BM, Levy G, Macdonald AJ, Burke SA, Wehling TO, Kern K, Damascelli A, Ast CR> ;Nano Lett.. 2015-05-13
• 213 citations
  First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors
  Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, K. Shah, Victor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, K. E. ...> ;Clinical Cancer Research. 2015 Jan 1
• 18 citations
  The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder allele
  Jill M. Johnsen, Gallia Levy, Randal J. Westrick, Priscilla K. Tucker, David Ginsburg> ;Mammalian Genome. 2008 Jan 11
• 18 citations
  Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene
  Heidi L. Lemmerhirt, Jordan A. Shavit, Gallia Levy, Suzanne M. Cole, Jeffrey C. Long, David Ginsburg> ;Blood. 2006 Nov 1
• 102 citations
  ADAMTS13 turns 3.
  Gallia Levy, David G. Motto, David Ginsburg> ;Blood. 2005 Jul 1
• 147 citations
  Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands
  Lesley G. Ellies, David Ditto, Gallia Levy, Mark G. Wahrenbrock, David Ginsburg, Ajit Varki, Dzung T. Le, Jamey D. Marth> ;Proceedings of the National Academy of Sciences of the United States of America. 2002 Jul 23
• 24 citations
  Cloning and characterization of zRICH, a 2',3'-cyclic-nucleotide 3'-phosphodiesterase induced during zebrafish optic nerve regeneration.
  Rafael P. Ballestero, Joseph A. Dybowski, Gallia Levy, Bernard W. Agranoff, Michael D. Uhler> ;Journal of Neurochemistry. 2001 Dec 25
• 1249 citations
  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura
  Gallia Levy, William C. Nichols, Eric C.-Y. Lian, Tatiana Foroud, Jeanette N. McClintick, Beth McGee, Angela Y. Yang, David R. Siemieniak, Kenneth R. Stark, Ralph A. G...> ;Nature. 2001 Oct 4
• Join now to see all

Journal Articles

• Emicizumab Prophylaxis in Patients Who Have Hemophilia A Without Inhibitors  
  Christine Kempton, Gallia G Levy, Michael U Callaghan, The New England Journal of Medicine

Abstracts/Posters

• Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3
  Gallia G. Levy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019